TC BioPharm (TCB) has been handed the right to become the only biotechnology company outside Japan to trial immunotherapy to treat patients with cancer.
The company has received a licence from the Medicines Healthcare Products Regulatory Agency (MHRA) to produce human cell therapy products at its clinical manufacturing facility in Lanarkshire.
The process is understood to be vital in the fight against cancer, and has already been trialled safely in Japan by Medinet, the Tokyo-listed immuno-cell therapy company.
Medinet holds 50 per cent of the shares in TCB and last year the two signed a strategic partnership which will see the Scottish firm clinically develop the process in the UK and Europe.
In simple terms, the process involves cultivating patients’ Gamma Delta or T cells which help the body fight cancer and serious viral infections.
Read press coverage in The Herald.